Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Neuraxis Inc.Eli Lilly
Last price
$7.40$1,273.46
Currency
USD
USD
$95M$1.2T
-43.86
-$0.78$29.79
1.470.45
0$6.69
00.53%
Sector
HealthHealth
Employees
2450,000
Ticker
$NRXS$LLY
Primary listing
AMEXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $NRXS or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.